NSG 533 Advanced Pharmacology
Exam 1 - Wilkes University
2026/2027 Academic Year
Verified Questions and Answers with Detailed Explanations
75 Questions | 5 Sections | Aligned with Advanced Pharmacology Competencies
Section 1: Foundational Pharmacology Principles (Q1-Q20)
Q1: A patient is prescribed a drug that follows first-order kinetics. The drug has a half-life of 4
hours. If the initial dose is 200 mg, how much drug remains in the body after 12 hours?
A. 25 mg [CORRECT]
B. 50 mg
C. 100 mg
D. 12.5 mg
Correct Answer: A
Rationale: In first-order kinetics, a constant fraction of the drug is eliminated per unit time. After each
half-life (4 hours), the amount remaining is halved. After 12 hours, three half-lives have elapsed ( =
3). Therefore, the remaining amount is 200 mg x (1/2)3 = 200 x 0.125 = 25 mg. This principle is
fundamental to understanding drug accumulation and dosing intervals for drugs with first-order
elimination, which includes the vast majority of medications.
Q2: Which phase of clinical trials primarily evaluates the safety and tolerability of a new drug
in healthy volunteers, and typically involves 20 to 80 participants?
A. Phase I [CORRECT]
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I clinical trials are the first stage of human testing and focus primarily on safety,
tolerability, pharmacokinetics, and pharmacodynamics. These trials are conducted in a small number of
healthy volunteers (20-80 subjects). Phase II trials evaluate efficacy and further assess safety in patients
with the target disease (100-300 participants). Phase III trials are large, multicenter studies that confirm
efficacy and monitor adverse reactions in diverse populations (1,000-3,000+ participants). Phase IV
trials are post-marketing surveillance studies conducted after FDA approval.
Q3: A patient with a genetic polymorphism in CYP2D6 is classified as an ultra-rapid
metabolizer. Which of the following is the most likely clinical consequence when this patient
receives codeine for pain management?
A. Reduced analgesic effect due to rapid conversion to inactive metabolites
B. Increased risk of opioid toxicity due to excessive morphine formation [CORRECT]
C. No effect because codeine is a prodrug independent of CYP2D6
D. Prolonged sedation due to delayed codeine elimination
Correct Answer: B
Rationale: Codeine is a prodrug that requires conversion to morphine via CYP2D6 for its analgesic effect.
Ultra-rapid metabolizers have increased CYP2D6 enzyme activity, leading to rapid and excessive
conversion of codeine to morphine. This can result in dangerously high morphine levels, causing
respiratory depression, sedation, and potentially fatal toxicity. The FDA has issued a boxed warning
Page 1
, NSG 533 Advanced Pharmacology Exam 1 - Wilkes University 2026/2027
against codeine use in CYP2D6 ultra-rapid metabolizers, particularly in children and postpartum women.
Genetic testing for CYP2D6 status is increasingly recommended before prescribing codeine-containing
products.
Q4: A highly protein-bound drug (98% bound) is administered concurrently with another drug
that displaces it from protein-binding sites. What is the most significant clinical effect of this
drug-drug interaction?
A. Increased clearance of the displaced drug leading to subtherapeutic levels
B. Transient increase in free (unbound) drug concentration potentially causing toxicity
[CORRECT]
C. Decreased volume of distribution of the displaced drug
D. Reduced renal excretion due to increased protein-drug complex formation
Correct Answer: B
Rationale: When a highly protein-bound drug is displaced from its binding sites, the immediate effect is a
transient increase in the free (pharmacologically active) fraction of the drug. This increase in free drug
concentration can lead to enhanced pharmacological effects and potential toxicity. However, the
increase is usually transient because the free drug is simultaneously cleared more rapidly (increased
metabolism and renal excretion), until a new steady state is achieved. This principle is clinically
important for drugs like warfarin and phenytoin, where even a small change in free fraction can have
significant clinical consequences.
Q5: The nurse is reviewing a medication that has a narrow therapeutic index. Which of the
following characteristics is most associated with drugs that have a narrow therapeutic index?
A. Wide margin of safety between the effective dose and the toxic dose
B. Small difference between the minimum effective concentration and the minimum toxic
concentration [CORRECT]
C. Low potential for drug-drug interactions
D. Rapid first-pass metabolism that reduces bioavailability consistently
Correct Answer: B
Rationale: A narrow therapeutic index (NTI) means there is a small difference between the dose or
concentration that produces the desired therapeutic effect and the dose or concentration that produces
toxicity. Drugs with a narrow therapeutic index require careful monitoring of serum drug levels and
individualized dosing. Common examples include digoxin, warfarin, lithium, phenytoin, theophylline, and
aminoglycosides. For these medications, small changes in dose, absorption, metabolism, or excretion can
lead to either therapeutic failure or serious toxicity. Therapeutic drug monitoring (TDM) is routinely
used for NTI drugs.
Q6: A drug has high first-pass metabolism. Which route of administration would bypass the
hepatic first-pass effect and result in the greatest bioavailability?
A. Oral administration
B. Sublingual administration [CORRECT]
C. Intramuscular injection
D. Rectal administration
Correct Answer: B
Rationale: First-pass metabolism refers to the pre-systemic elimination of a drug by the liver before it
reaches the systemic circulation, primarily occurring after oral administration. The sublingual route
bypasses the hepatic portal circulation because the venous drainage from the sublingual mucosa enters
the systemic circulation directly via the superior vena cava, rather than passing through the portal vein
to the liver. Intramuscular injection also partially bypasses first-pass metabolism but some drug may still
reach the liver via systemic circulation. Rectal administration partially bypasses first-pass
(approximately 50-70% avoids the portal system). Oral administration results in the highest first-pass
Page 2
, NSG 533 Advanced Pharmacology Exam 1 - Wilkes University 2026/2027
effect.
Q7: A 70-year-old patient with chronic kidney disease (CKD) stage 4 is prescribed a renally
cleared drug. Which pharmacokinetic parameter is most important to adjust in this patient?
A. Volume of distribution
B. Absorption rate constant
C. Clearance and elimination half-life [CORRECT]
D. Protein binding affinity
Correct Answer: C
Rationale: In patients with chronic kidney disease, the primary pharmacokinetic changes that affect drug
dosing are decreased renal clearance and prolonged elimination half-life for drugs that are
predominantly eliminated by the kidneys. As glomerular filtration rate (GFR) declines, the rate of drug
elimination decreases proportionally, leading to drug accumulation if dosing intervals are not extended
or doses reduced. The Cockcroft-Gault equation or the CKD-EPI equation is used to estimate creatinine
clearance and guide dose adjustments. Volume of distribution and protein binding may also be altered in
CKD but are less directly consequential for dosing adjustments than clearance changes.
Q8: Which cytochrome P450 (CYP) enzyme is responsible for metabolizing the largest number
of commonly prescribed drugs and is the most frequent site of drug-drug interactions?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 is the most abundant cytochrome P450 enzyme in the human liver and intestines, and
it is responsible for the metabolism of approximately 50% of all clinically used drugs. It metabolizes a
wide range of medication classes including statins, calcium channel blockers, benzodiazepines,
macrolide antibiotics, and many others. Because of its broad substrate specificity, CYP3A4 is the most
common site of drug-drug interactions involving enzyme inhibition or induction. Both CYP3A4 inhibitors
(e.g., ketoconazole, ritonavir, grapefruit juice) and inducers (e.g., rifampin, St. John wort,
carbamazepine) can significantly alter the plasma levels of CYP3A4 substrates.
Q9: A patient taking a CYP3A4 inhibitor (ketoconazole) is started on simvastatin. What is the
expected pharmacokinetic effect and the primary clinical concern?
A. Decreased simvastatin levels leading to reduced cholesterol-lowering effect
B. Increased simvastatin levels leading to elevated risk of myopathy and rhabdomyolysis
[CORRECT]
C. No significant interaction because simvastatin is metabolized by CYP2C9
D. Accelerated renal clearance of simvastatin resulting in subtherapeutic levels
Correct Answer: B
Rationale: Simvastatin is a substrate of CYP3A4, and ketoconazole is a potent CYP3A4 inhibitor. When
these drugs are co-administered, the inhibition of CYP3A4 reduces simvastatin metabolism, leading to
significantly elevated simvastatin plasma concentrations. This increase raises the risk of
statin-associated muscle toxicity, including myopathy and rhabdomyolysis, which can be life-threatening.
The FDA recommends avoiding concurrent use of simvastatin with strong CYP3A4 inhibitors, or using
alternative statins (e.g., pravastatin or rosuvastatin) that are less dependent on CYP3A4 metabolism.
Q10: The therapeutic index (TI) of a drug is calculated as the ratio of which two values?
A. ED50 to LD50
B. LD50 to ED50
Page 3
Exam 1 - Wilkes University
2026/2027 Academic Year
Verified Questions and Answers with Detailed Explanations
75 Questions | 5 Sections | Aligned with Advanced Pharmacology Competencies
Section 1: Foundational Pharmacology Principles (Q1-Q20)
Q1: A patient is prescribed a drug that follows first-order kinetics. The drug has a half-life of 4
hours. If the initial dose is 200 mg, how much drug remains in the body after 12 hours?
A. 25 mg [CORRECT]
B. 50 mg
C. 100 mg
D. 12.5 mg
Correct Answer: A
Rationale: In first-order kinetics, a constant fraction of the drug is eliminated per unit time. After each
half-life (4 hours), the amount remaining is halved. After 12 hours, three half-lives have elapsed ( =
3). Therefore, the remaining amount is 200 mg x (1/2)3 = 200 x 0.125 = 25 mg. This principle is
fundamental to understanding drug accumulation and dosing intervals for drugs with first-order
elimination, which includes the vast majority of medications.
Q2: Which phase of clinical trials primarily evaluates the safety and tolerability of a new drug
in healthy volunteers, and typically involves 20 to 80 participants?
A. Phase I [CORRECT]
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: A
Rationale: Phase I clinical trials are the first stage of human testing and focus primarily on safety,
tolerability, pharmacokinetics, and pharmacodynamics. These trials are conducted in a small number of
healthy volunteers (20-80 subjects). Phase II trials evaluate efficacy and further assess safety in patients
with the target disease (100-300 participants). Phase III trials are large, multicenter studies that confirm
efficacy and monitor adverse reactions in diverse populations (1,000-3,000+ participants). Phase IV
trials are post-marketing surveillance studies conducted after FDA approval.
Q3: A patient with a genetic polymorphism in CYP2D6 is classified as an ultra-rapid
metabolizer. Which of the following is the most likely clinical consequence when this patient
receives codeine for pain management?
A. Reduced analgesic effect due to rapid conversion to inactive metabolites
B. Increased risk of opioid toxicity due to excessive morphine formation [CORRECT]
C. No effect because codeine is a prodrug independent of CYP2D6
D. Prolonged sedation due to delayed codeine elimination
Correct Answer: B
Rationale: Codeine is a prodrug that requires conversion to morphine via CYP2D6 for its analgesic effect.
Ultra-rapid metabolizers have increased CYP2D6 enzyme activity, leading to rapid and excessive
conversion of codeine to morphine. This can result in dangerously high morphine levels, causing
respiratory depression, sedation, and potentially fatal toxicity. The FDA has issued a boxed warning
Page 1
, NSG 533 Advanced Pharmacology Exam 1 - Wilkes University 2026/2027
against codeine use in CYP2D6 ultra-rapid metabolizers, particularly in children and postpartum women.
Genetic testing for CYP2D6 status is increasingly recommended before prescribing codeine-containing
products.
Q4: A highly protein-bound drug (98% bound) is administered concurrently with another drug
that displaces it from protein-binding sites. What is the most significant clinical effect of this
drug-drug interaction?
A. Increased clearance of the displaced drug leading to subtherapeutic levels
B. Transient increase in free (unbound) drug concentration potentially causing toxicity
[CORRECT]
C. Decreased volume of distribution of the displaced drug
D. Reduced renal excretion due to increased protein-drug complex formation
Correct Answer: B
Rationale: When a highly protein-bound drug is displaced from its binding sites, the immediate effect is a
transient increase in the free (pharmacologically active) fraction of the drug. This increase in free drug
concentration can lead to enhanced pharmacological effects and potential toxicity. However, the
increase is usually transient because the free drug is simultaneously cleared more rapidly (increased
metabolism and renal excretion), until a new steady state is achieved. This principle is clinically
important for drugs like warfarin and phenytoin, where even a small change in free fraction can have
significant clinical consequences.
Q5: The nurse is reviewing a medication that has a narrow therapeutic index. Which of the
following characteristics is most associated with drugs that have a narrow therapeutic index?
A. Wide margin of safety between the effective dose and the toxic dose
B. Small difference between the minimum effective concentration and the minimum toxic
concentration [CORRECT]
C. Low potential for drug-drug interactions
D. Rapid first-pass metabolism that reduces bioavailability consistently
Correct Answer: B
Rationale: A narrow therapeutic index (NTI) means there is a small difference between the dose or
concentration that produces the desired therapeutic effect and the dose or concentration that produces
toxicity. Drugs with a narrow therapeutic index require careful monitoring of serum drug levels and
individualized dosing. Common examples include digoxin, warfarin, lithium, phenytoin, theophylline, and
aminoglycosides. For these medications, small changes in dose, absorption, metabolism, or excretion can
lead to either therapeutic failure or serious toxicity. Therapeutic drug monitoring (TDM) is routinely
used for NTI drugs.
Q6: A drug has high first-pass metabolism. Which route of administration would bypass the
hepatic first-pass effect and result in the greatest bioavailability?
A. Oral administration
B. Sublingual administration [CORRECT]
C. Intramuscular injection
D. Rectal administration
Correct Answer: B
Rationale: First-pass metabolism refers to the pre-systemic elimination of a drug by the liver before it
reaches the systemic circulation, primarily occurring after oral administration. The sublingual route
bypasses the hepatic portal circulation because the venous drainage from the sublingual mucosa enters
the systemic circulation directly via the superior vena cava, rather than passing through the portal vein
to the liver. Intramuscular injection also partially bypasses first-pass metabolism but some drug may still
reach the liver via systemic circulation. Rectal administration partially bypasses first-pass
(approximately 50-70% avoids the portal system). Oral administration results in the highest first-pass
Page 2
, NSG 533 Advanced Pharmacology Exam 1 - Wilkes University 2026/2027
effect.
Q7: A 70-year-old patient with chronic kidney disease (CKD) stage 4 is prescribed a renally
cleared drug. Which pharmacokinetic parameter is most important to adjust in this patient?
A. Volume of distribution
B. Absorption rate constant
C. Clearance and elimination half-life [CORRECT]
D. Protein binding affinity
Correct Answer: C
Rationale: In patients with chronic kidney disease, the primary pharmacokinetic changes that affect drug
dosing are decreased renal clearance and prolonged elimination half-life for drugs that are
predominantly eliminated by the kidneys. As glomerular filtration rate (GFR) declines, the rate of drug
elimination decreases proportionally, leading to drug accumulation if dosing intervals are not extended
or doses reduced. The Cockcroft-Gault equation or the CKD-EPI equation is used to estimate creatinine
clearance and guide dose adjustments. Volume of distribution and protein binding may also be altered in
CKD but are less directly consequential for dosing adjustments than clearance changes.
Q8: Which cytochrome P450 (CYP) enzyme is responsible for metabolizing the largest number
of commonly prescribed drugs and is the most frequent site of drug-drug interactions?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 is the most abundant cytochrome P450 enzyme in the human liver and intestines, and
it is responsible for the metabolism of approximately 50% of all clinically used drugs. It metabolizes a
wide range of medication classes including statins, calcium channel blockers, benzodiazepines,
macrolide antibiotics, and many others. Because of its broad substrate specificity, CYP3A4 is the most
common site of drug-drug interactions involving enzyme inhibition or induction. Both CYP3A4 inhibitors
(e.g., ketoconazole, ritonavir, grapefruit juice) and inducers (e.g., rifampin, St. John wort,
carbamazepine) can significantly alter the plasma levels of CYP3A4 substrates.
Q9: A patient taking a CYP3A4 inhibitor (ketoconazole) is started on simvastatin. What is the
expected pharmacokinetic effect and the primary clinical concern?
A. Decreased simvastatin levels leading to reduced cholesterol-lowering effect
B. Increased simvastatin levels leading to elevated risk of myopathy and rhabdomyolysis
[CORRECT]
C. No significant interaction because simvastatin is metabolized by CYP2C9
D. Accelerated renal clearance of simvastatin resulting in subtherapeutic levels
Correct Answer: B
Rationale: Simvastatin is a substrate of CYP3A4, and ketoconazole is a potent CYP3A4 inhibitor. When
these drugs are co-administered, the inhibition of CYP3A4 reduces simvastatin metabolism, leading to
significantly elevated simvastatin plasma concentrations. This increase raises the risk of
statin-associated muscle toxicity, including myopathy and rhabdomyolysis, which can be life-threatening.
The FDA recommends avoiding concurrent use of simvastatin with strong CYP3A4 inhibitors, or using
alternative statins (e.g., pravastatin or rosuvastatin) that are less dependent on CYP3A4 metabolism.
Q10: The therapeutic index (TI) of a drug is calculated as the ratio of which two values?
A. ED50 to LD50
B. LD50 to ED50
Page 3
